Navigation Links
Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections
Date:11/23/2008

ral infection of cells. Our data go a step further, providing compelling evidence that exposed PS itself is a promising anti-viral drug target that is involved in the pathogenesis of multiple viruses, suggesting the possibility of achieving broad-spectrum anti-viral effects using a single anti-PS agent. We look forward to further exploring the potential of bavituximab and other anti-PS antibodies against viruses for which there are few or no effective therapeutic options."

In the first study, 100% of mice infected with lethal murine CMV and treated with bavituximab recovered fully, while only 25% of control animals survived. In the second study, guinea pigs were infected with lethal Pichinde virus, which is a model virus for Lassa fever. Fifty percent of the bavituximab-treated group survived, while untreated animals all died. In this study, the anti-viral effect of bavituximab was further augmented by the addition of the standard of care drug ribavirin, with 63% of animals receiving the combination therapy surviving the potentially lethal infection.

"We are extremely pleased to see this research demonstrating the broad anti-viral potential of bavituximab and our anti-PS technology platform published in this highly regarded journal," said Steven W. King, president and CEO of Peregrine. "This new publication is the latest in a series of external validations of our anti-viral program. It follows a recently awarded federal government contract for assessment of anti-PS antibodies to treat viral hemorrhagic fevers, research on the role of PS in viral infections that was published in a leading science journal earlier this year, and a recent presentation on anti-PS antibodies at a global HIV conference."

Mr. King added, "Better prevention and treatment of viral diseases are urgently needed, and we are increasingly optimistic that bavituximab and our other anti-PS antibodies could be valuable contributors to the field."

PS i
'/>"/>

Contact: Barbara Lindheim
blindheim@biocompartners.com
212-918-4650
BioCom Partners
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Nature study demonstrates that bacterial clotting depends on clustering
2. Extreme nature helps scientists design nano materials
3. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
4. Cancer signatures uncovered
5. Nature publishes new evidence about the deep biosphere written by biogeoscientists
6. Dartmouth researchers discover gene signatures for scleroderma
7. Scattered nature of Wisconsins woodlands could complicate forests response to climate change
8. Giving nature a helping hand
9. A molecular switch turns on the flame in natures blowtorch
10. Male seahorses are natures Mr. Mom, Texas A&M researchers say
11. Nature paper describes technique for extracting hierarchical structure of networks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:3/2/2015)... 2015   Neurotechnology , a provider of high-precision ... SentiGaze Software Development Kit (SDK). The SentiGaze algorithm ... off-the-shelf webcams to track eye movements and generate heatmaps ... Heatmaps can be used for applications such as analysis ... The SDK can also be used to develop interfaces ...
(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2
... J. Fox Foundation for Parkinson,s Research today announced ... research teams under its Target Validation initiative. This ... to help push potential PD drug targets forward ... million Parkinson,s patients worldwide. "The discovery of ...
... account for almost 50% of crop sales in the ... ensure good quality. But more information is needed about ... changes so that management practices such as irrigation can ... generalize because of variations in crops, planting densities, and ...
... The AIDS Vaccine Advocacy Coalition (AVAC) today urged Dr. Anthony ... Diseases (NIAID) to act swiftly to clarify the path ahead ... with the proposed PAVE 100 AIDS vaccine trial but would, ... also calls on leaders in the field to make clear ...
Cached Biology News:Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinson's 2Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinson's 3Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinson's 4Digital cameras, remote satellites measure crop water demand 2AVAC comments on NIAID decision not to move forward with PAVE 100 Trial 2AVAC comments on NIAID decision not to move forward with PAVE 100 Trial 3
(Date:3/5/2015)... Bi-Biomics today announced a discovery made ... The improvement in histological quality provided the detail ... all daughter cells. , After processing with Ultralight ... at 1000-1600x using light microscopy. Phylogenetic and ... daughter cells displayed predominant binary features --- one ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) ... Outlook 2015: New Therapy Ventures Pave the Way for ... All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen ... given a positive return and hence increased the interest ... select therapy/niche indication where the high treatment cost justifies ...
(Date:3/5/2015)... Southlake, Texas (PRWEB) March 05, 2015 ... treatment of acute and chronic orthopedic conditions such ... runner’s knee, tennis elbow, and joint pain due ... also be administered during orthopedic surgeries to promote ... patented scientific advances in nearly pain-free bone marrow ...
(Date:3/4/2015)... 2015  Brooklyn residents now have a new place ... and injuries. Nunzio Saulle , M.D., a board-certified ... his NJS Physical Medicine and Rehabilitation (PM&R) practice in ... 5, 2015. Health Plus Management, LLC is managing the ... 1178 Flatbush Avenue. This new PM&R practice will treat ...
Breaking Biology Technology:Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... Mass. and CHICAGO, March 29 Boston,Scientific Corporation ... an analysis,of two-year data from more than 7,000 ... was designed to evaluate the safety performance of ... in "real-world" practice. Outcomes through two years in ...
... MINRAD,International, Inc. (Amex: BUF ) today announced its ... as President and Chief,Operating Officer, effective April 1, 2008, ... Company. Mr. DiGiacinto,s appointment is the,first step in a ... the Company beginning on January 1, 2009. William H. ...
... Aerovance Inc. today,announced it has secured $20 ... the syndicate, which includes Silicon Valley Bank,and Comerica ... financing line,at closing. The remaining $10 million is ... financing reflects continued interest and enthusiasm in Aerovance,and ...
Cached Biology Technology:Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 2Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 3Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 4MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer 2MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer 3MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer 4
A Highly Purified, Cost-Effective Taq DNA Polymerase...
...
... Neogens enzyme-linked immunosorbent assay (ELISA) ... as screening devices for the detection of ... The kits are intended for forensic use ... samples be confirmed by a quantitative method ...
96 Well Base Plate...
Biology Products: